PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation

Colorectal cancer (CRC) is the second leading cause of cancer death worldwide, and immune checkpoint blockade therapy provides an opportunity for improving the outcome of CRC patients. Recent studies suggest that programmed death ligand-1 (PD-L1) is only expressed in 12% of CRCs. Here, we demonstrat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncoimmunology
Egile Nagusiak: Wang, Huanbin, Yao, Han, Li, Chushu, Liang, Lunxi, Zhang, Yao, Shi, Hubing, Zhou, Chongzhi, Chen, Yingxuan, Fang, Jing-Yuan, Xu, Jie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2017
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543903/
https://ncbi.nlm.nih.gov/pubmed/28811964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1327494
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak